
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the DoH

Fully registered clinical trials unit specialising in the design, conduct and analysis of definitive clinical trials and test evaluation studies.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the DoH

Lisa Kelly, BASIL Research Nurse at Solihull Research Showcase – celebrating BASIL trials for International Trials Day!

CReST showed that stenting as a bridge to surgery reduces stoma formation without detrimental effects in colon cancer patients with left-sided colonic obstruction #ICTD2023 @BJSurgery tinyurl.com/2p9uh8s8

Recruiting from 80 hospitals in 7 global south countries, @CheetahRct found that 1 in 8 surgical site infections could be prevented by changing gloves and instruments before fascial closure for abdominal surgery @TheLancet @NIHR_GSU #ICTD2023 tinyurl.com/4p32e4p3

The @STOPACEi_trial showed that in people with advanced and progressive chronic kidney disease, discontinuation of RAS inhibitors was not associated with difference in rate of decrease in kidney function measured using eGFR @NEJM #ICTD2023 tinyurl.com/42whfnwd


Published in @JCO_ASCO, FOxTROT showed that six weeks of preoperative chemotherapy for operable colon cancer can be delivered safely and provides better 2-year disease control #ICTD2023 tinyurl.com/4mmmm5sj

Funded by @gatesfoundation, the @EmotiveTrial cluster randomised trial showed an immense 60% reduction in severe postpartum haemorrhage after vaginal delivery, reducing the risk of haemorrhage-related maternal death @NEJM #ICTD2023 tinyurl.com/ydn86mbz

BCTU, a UKCRC registered trials unit was 25 years old in 2022. Clinical Trial Units play a key role in the design and delivery of clinical trials. To celebrate #ClinicalTrialsDay we will be tweeting about some of the trials we have delivered over the past 12 months.

Proud beyond words of the work of colleagues from @unibirmingham @unibirm_MDS @IMSR_UoB @UoB_IAHR Partnering with the @WHO and @gatesfoundation , implementation of the intervention would have huge impact .

I’m very encouraged by the E-MOTIVE Trial results released today at #IMNHC2023 to treat postpartum hemorrhage, the #1 cause of maternal mortality. This new approach led by @unibirmingham and @WHO could drastically improve women’s chances of surviving childbirth globally. b-gat.es/3BclMsw

If anyone is interested to know more about FOxTROT, @JenSeligmann's tweetorial is essential Friday lunchtime reading!
🥁🥁🥁Tweetorial FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer We report that NAC is ✅deliverable and safe ✅led to statistically significant reduction in cancer recurrence than upfront surgery A 🧵 (1/14) #crcsm ascopubs.org/doi/full/10.120…

🥁🥁🥁Tweetorial FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer We report that NAC is ✅deliverable and safe ✅led to statistically significant reduction in cancer recurrence than upfront surgery A 🧵 (1/14) #crcsm ascopubs.org/doi/full/10.120…

Lots of questions emerging about #obstructionrisk in @FoxtrotStudy #NAC group❓ We've done a deep dive into this in upcoming #analysis (available Q2 2023) @BASO_ACS @RSMcoloproct 🔬 A (short) thread 🧵 @young_bjs @YouESCP @escp_tweets @ACPGBI @juliomayol @JenSeligmann (1/X)
🥁🥁🥁Tweetorial FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer We report that NAC is ✅deliverable and safe ✅led to statistically significant reduction in cancer recurrence than upfront surgery A 🧵 (1/14) #crcsm ascopubs.org/doi/full/10.120…

📢 News: FOxTROT, a trial we funded, has shown that starting chemotherapy before surgery, instead of after, can significantly cut the risk of colon cancer coming back. The findings could change how doctors treat colon cancer in the NHS and around the world https://t.co/kwfo5LX9M2

Thank you to @guardian @GdnHealthcare for featuring the FOxTROT trial results in today's publication! theguardian.com/society/2023…